Incannex completes positive pre-ind meeting with us fda on ihl-675a for treatment of rheumatoid arthritis

Melbourne, australia, july 26, 2023 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed a constructive pre-investigational new drug application (‘pre-ind') meeting with the u.s. food and drug administration (‘fda') for its proprietary drug product ihl-675a for treatment of rheumatoid arthritis (‘ra').
IXHL Ratings Summary
IXHL Quant Ranking